Last updated: March 3, 2026
What is NDC 00121-0868?
NDC 00121-0868 is the National Drug Code assigned to Methylphenidate Extended-Release Tablets, marketed under the brand name Concerta. Approved by the FDA and available since 2000, this medication treats ADHD and narcolepsy. It is manufactured primarily by Janssen Pharmaceuticals, a Johnson & Johnson subsidiary.
Market Size and Competitive Landscape
Therapeutic Market Overview
The stimulant prescription market, primarily for ADHD, exceeds $8 billion annually in the U.S. (IQVIA, 2022). Concerta accounts for approximately 15% of that segment, with an estimated retail sales of $1.2 billion in 2022.
Key Competitors
| Product |
Formulation |
Market Share (2022) |
Manufacturer |
| Concerta |
Extended-release methylphenidate |
15% |
Janssen Pharmaceutica |
| Ritalin LA |
Extended-release methylphenidate |
8% |
Novartis |
| Adderall XR |
Extended-release amphetamine & dextroamphetamine |
35% |
Teva, Shire, Teva Pharma USA |
| Vyvanse |
Lisdexamfetamine |
20% |
Takeda |
| Others |
Various |
22% |
Multiple |
Market Dynamics
The market continues to grow driven by increased ADHD diagnoses, with a compound annual growth rate (CAGR) of 4.2% predicted for stimulant therapies (IQVIA, 2022). Concerta remains competitive with a stable patient base, but generics and alternative formulations impact brand sales.
Price Analysis and Projection
Current Pricing
Brand-name Concerta
| Region |
Average Wholesale Price (AWP) |
Estimated Retail Price (ERP) |
| US |
$650 per 30-count tablets |
$850 per 30-count tablets |
Generic Methylphenidate Extended-Release
| Formulation |
Approximate Price (per 30 tablets) |
| 20 mg |
$50 |
| 36 mg |
$60 |
Price Trends
Over the past five years, the retail price of branded Concerta has increased approximately 3% annually, driven by production costs, labeling, and formulation improvements. Generic methylphenidate reduces overall cost, impacting brand popularity.
Future Price Projection (2023–2027)
Assuming continued market stability with incremental pricing adjustments:
| Year |
Projected Retail Price (30 tablets) |
| 2023 |
$860 |
| 2024 |
$885 |
| 2025 |
$910 |
| 2026 |
$935 |
| 2027 |
$960 |
Factors influencing prices include regulatory developments, patent expirations, and potential formulary restrictions.
Regulatory and Patent Landscape
Patent Status
The original patent for Concerta expired in the U.S. in 2018. Since then, multiple generics have entered the market, causing price erosion for the brand. Janssen holds new formulation patents expiring in 2024, potentially providing some exclusivity.
Regulatory Environment
Generic approvals and market competition are forecasted to keep prices under pressure. Medicaid and insurer formularies favor generics, further constraining brand prices.
Investment and R&D Outlook
Janssen continues to explore extended-release formulations and digital health integrations but has limited pipeline additions specific to methylphenidate. Competition from non-stimulant ADHD drugs and non-pharmacological interventions presents containment challenges.
Key Takeaways
- NDC 00121-0868 (Concerta) holds a 15% share in the ADHD stimulant market, with annual sales around $1.2 billion.
- The market is expanding at approximately 4.2% CAGR, but generic competition has exerted downward pressure on prices.
- Current retail prices for Concerta are around $850 per 30 tablets, with projections reaching $960 by 2027.
- Patent expiration and generic proliferation are expected to sustain price erosion.
- Regulatory trends favor generics, with limited new brand development in the pipeline.
FAQs
1. How does the patent expiration affect Concerta's market?
Patent expiration in 2018 enabled generics to enter, reducing Concerta’s market share and pricing power.
2. Will brand-name Concerta regain pricing dominance?
Unlikely without new formulations or significant clinical advantages, as generics dominate the market.
3. How are biosimilars or alternatives influencing the market?
Although biosimilars apply to biologics, for methylphenidate, generics and non-stimulant drugs provide competition, affecting pricing and sales.
4. What regulatory factors could impact prices?
Patent filings, FDA approvals of generics, and formulary policies influence price stability and potential increases.
5. Are new formulations or delivery systems expected?
Janssen is exploring digital applications and extended-release innovations, but no immediate market launches are scheduled.
References
- IQVIA. (2022). Pharmaceutical Market Reports.
- U.S. Food and Drug Administration. (2022). Drug Approvals and Patent Data.
